Pivotal Bioventure Partners Investment Advisor
$308M 13F equity value
14 Holdings
Quarter ended June 30, 2026
The latest 13F on file for Pivotal Bioventure Partners Investment Advisor covers the quarter ended June 30, 2026. Institutional managers report holdings quarterly to the SEC, so each filing is a snapshot of positions held on that date.
Top Holdings
| Ticker | Company | Shares | Value | Weight |
|---|---|---|---|---|
| PCVX | VAXCYTE INC | 1,425,470 | $83M | 26.9% |
| ARQT | ARCUTIS BIOTHERAPEUTICS INC | 1,265,283 | $33M | 10.8% |
| TRVI | TREVI THERAPEUTICS INC | 1,742,672 | $33M | 10.6% |
| AVLN | AVALYN PHARMACEUTICALS INC | 966,792 | $32M | 10.3% |
| EVMN | EVOMMUNE INC | 1,926,943 | $26M | 8.3% |
| MPLT | MAPLIGHT THERAPEUTICS INC | 611,446 | $22M | 7.1% |
| OCS | OCULIS HOLDING AG | 1,506,250 | $21M | 6.8% |
| BIOA | BIOAGE LABS INC | 653,374 | $16M | 5.2% |
| IMNM | IMMUNOME INC | 732,512 | $16M | 5.0% |
| ZBIO | ZENAS BIOPHARMA INC | 490,766 | $12M | 4.0% |
Track Pivotal Bioventure Partners Investment Advisor's 13F portfolio: $308M in reported holdings, 14 positions. Top holdings and quarterly changes on SentiSense.
This page is powered by the SentiSense API: GET /api/v1/institutional/institution/{slugOrCik}